Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O14793

UPID:
GDF8_HUMAN

ALTERNATIVE NAMES:
Myostatin

ALTERNATIVE UPACC:
O14793; A1C2J7; A1C2K0; Q6B0H2

BACKGROUND:
Myostatin, also referred to as Growth/differentiation factor 8, is a key regulator of muscle mass. By inhibiting skeletal muscle growth, Myostatin ensures the balance and proper development of muscle tissue. Its role is critical in preventing unchecked muscle growth, which could lead to physiological imbalances.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Myostatin could open doors to potential therapeutic strategies. Given its involvement in Muscle hypertrophy, a condition characterized by abnormal muscle growth, targeting Myostatin could offer new avenues for enhancing muscle strength and bulk in various muscle-wasting diseases. This approach holds promise for improving the quality of life for individuals affected by such conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.